The Neuroblastoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neuroblastoma pipeline products will significantly revolutionize the Neuroblastoma market dynamics.
Neuroblastoma Overview
Neuroblastoma is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells). It is derived from two words i.e. “neuro” means nerves and “blastoma” refers to the tumor affecting the immature or developing cells. It originates in the adrenal medulla and paraspinal or periaortic regions where sympathetic nervous system tissue is present.
Stages of neuroblastoma determine the extent of spread of the tumor in the patients, and the disease is staged on the basis of results of physical exams, imaging tests, and biopsies of the main tumor and other tissues.
Some of the key facts of the Neuroblastoma Market Report:
- The Neuroblastoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- In December 2021, Phase II data of hu14.18K322A was published at ASCO journal, data showed improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemoimmunotherapy
- In September 2021, Y-mAbs Therapeutics presented data from phase II trial of Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma
- According to a study conducted by Shohet et al., the median time to relapse is around 1.5 years from diagnosis
- Key Neuroblastoma Companies: Clarity Pharmaceuticals, Y-mabs therapeutics, Eli Lilly, LaboratorioElea Phoenix, K C Pharmaceuticals, AutolusTherapeutics, and others
- Key Neuroblastoma Therapies: 67Cu-SARTATE, Omburtamab, LY 3295668, Racotumomab, Eflornithine, AUTO6NG, and others
- The Neuroblastoma epidemiology based on gender analyzed that Neuroblastoma affects males slightly more than females
Get a Free sample for the Neuroblastoma Market Report
Key benefits of the Neuroblastoma Market report:
- Neuroblastoma market report covers a descriptive overview and comprehensive insight of the Neuroblastoma Epidemiology and Neuroblastoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Neuroblastoma market report provides insights on the current and emerging therapies.
- Neuroblastoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Neuroblastoma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Neuroblastoma market.
Discover more about therapies set to grab major Neuroblastoma market share @ Neuroblastoma market forecast
Neuroblastoma Epidemiology Segmentation:
The Neuroblastoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Neuroblastoma
- Prevalent Cases of Neuroblastoma by severity
- Gender-specific Prevalence of Neuroblastoma
- Diagnosed Cases of Episodic and Chronic Neuroblastoma
Neuroblastoma Market
The dynamics of the Neuroblastoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as LY 3295668, Racotumomab, and others during the forecasted period 2019-2032.
Download the report to understand which factors are driving Neuroblastoma epidemiology trends @ Neuroblastoma Epidemiological Insights
Neuroblastoma Market Strengths
- The neuroblasts may cause due to the immature cell growth or mutation in the gene responsible for controlling cell proliferation
- The increasing cases of childhood cancer, rising research on Neuroblastoma treatment and increasing spending on cancer treatment is expected to drive market growth over the forecast period
Neuroblastoma Therapies and Key Companies
- 67Cu-SARTATE: Clarity Pharmaceuticals
- Omburtamab: Y-mabs therapeutics
- LY 3295668: Eli Lilly
- Racotumomab: LaboratorioElea Phoenix
- Eflornithine: K C Pharmaceuticals
- AUTO6NG: AutolusTherapeutics
Scope of the Neuroblastoma Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Neuroblastoma Companies: Clarity Pharmaceuticals, Y-mabs therapeutics, Eli Lilly, LaboratorioElea Phoenix, K C Pharmaceuticals, AutolusTherapeutics, and others
- Key Neuroblastoma Therapies: 67Cu-SARTATE, Omburtamab, LY 3295668, Racotumomab, Eflornithine, AUTO6NG, and others
- Neuroblastoma Therapeutic Assessment: Neuroblastoma current marketed and Neuroblastoma emerging therapies
- Neuroblastoma Market Dynamics: Neuroblastoma market drivers and Neuroblastoma market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Neuroblastoma Market Access and Reimbursement
Neuroblastoma Market Opportunities
- Understanding of neuroblastoma biology deepens, our approaches to therapy for this disease continue to evolve Improved risk stratification and the use of predictive biomarkers will aid in treatment selection for patients with neuroblastoma, and it is expected that future treatments will be associated with greater efficacy and less toxicity
Table of Contents
1. Neuroblastoma Market Report Introduction
2. Executive Summary for Neuroblastoma
3. SWOT analysis of Neuroblastoma
4. Neuroblastoma Patient Share (%) Overview at a Glance
5. Neuroblastoma Market Overview at a Glance
6. Neuroblastoma Disease Background and Overview
7. Neuroblastoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Neuroblastoma
9. Neuroblastoma Current Treatment and Medical Practices
10. Neuroblastoma Unmet Needs
11. Neuroblastoma Emerging Therapies
12. Neuroblastoma Market Outlook
13. Country-Wise Neuroblastoma Market Analysis (2019–2032)
14. Neuroblastoma Market Access and Reimbursement of Therapies
15. Neuroblastoma Market Drivers
16. Neuroblastoma Market Barriers
17. Neuroblastoma Appendix
18. Neuroblastoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Neuroblastoma treatment, visit @ Neuroblastoma Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/